Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1

Selective sodium–glucose cotransporter 2 (SGLT2) inhibitors reduced the risk of hospitalization for heart failure in patients with or without type 2 diabetes (T2DM) in large-scale clinical trials. The exact mechanism of action is currently unclear. The dual SGLT1/2 inhibitor sotagliflozin not only r...

Full description

Bibliographic Details
Main Authors: Alex Ali Sayour, Mihály Ruppert, Attila Oláh, Kálmán Benke, Bálint András Barta, Eszter Zsáry, Béla Merkely, Tamás Radovits
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:International Journal of Molecular Sciences
Subjects:
sodium–glucose cotransporter 1
SGLT2 inhibitor
dual SGLT1/2 inhibitor
heart failure
myocardial ischemia
empagliflozin
Online Access:https://www.mdpi.com/1422-0067/22/18/9852

Similar Items

Similar Items